Previous close | 0.0006 |
Open | 0.0005 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 0.0005 - 0.0006 |
52-week range | 0.0005 - 0.0033 |
Volume | |
Avg. volume | 19,166,551 |
Market cap | 2.327M |
Beta (5Y monthly) | 1.33 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.0000 |
Earnings date | 16 May 2024 - 20 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
ELK CITY, Idaho, March 04, 2024--Therapeutic Solutions International, Inc. (TSOI), a clinical-stage stem cell and immunotherapy company, announced today the granting of a patent covering the ability of QuadraMune® and similar compositions, to stimulate natural killer (NK) cell activity in patients with COVID-19. NK cells are the first line of defense against viruses and cancers1.
ELK CITY, Idaho, February 29, 2024--Therapeutic Solutions International, Inc. (TSOI), announced today results of ongoing experiments demonstrating that the healing effects of JadiCells appear to be mediated by a biological mechanism involving interplay between two types of immunological cells found in the body.
ELK CITY, Idaho, February 26, 2024--Therapeutic Solutions International, Inc. (TSOI), announced today data demonstrating that JadiCell administration is capable of increasing gene therapy mediated production of therapeutic cells in vivo.